Pharmaceuticals company Strides Pharma Science announced Q1FY25 results: Revenues at Rs 10,875 million, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264 bps YoY to 61.3% EBITDA grew by 28.7% YoY to Rs 2,170 million with EBITDA margin at 20%, a growth of 187 bps YoY US revenues at a historic high of USD 70 million in Q1FY25, a growth of 24.5% YoY Q1FY25 Adjusted PAT at Rs 839 million and Reported PAT at Rs 683 million Reported EPS at Rs 7.6 and Adj EPS at Rs 9.1 for Q1FY25 Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook. The company achieved critical thresholds of 20% EBITDA margin, Rs 683m of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business. The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.” Result PDF